Correction: Efficient and Reproducible Myogenic Differentiation from Human iPS Cells: Prospects for Modeling Miyoshi Myopathy In Vitro

Tanaka, Akihito; Woltjen, Knut; Miyake, Katsuya; Hotta, Akitsu; Ikeya, Motoji; Yamamoto, Takuya; Nishino, Tokiko; Shoji, Emi; Sehara-Fujisawa, Atsuko; Manabe, Yasuko; Fujii, Nobuharu; Hanaoka, Kazunori; Era, Takumi; Yamashita, Satoshi; Isobe, Ken‐ichi; Kimura, En; Sakurai, Hiroyuki

doi:10.1371/annotation/63972dc9-3a31-43d0-ad52-bc46fd948c03

Cited by 49 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, several culture protocols have been developed to derive skeletal myocytes from human PSCs. Transgene-based SMPC derivation uses the overexpression of myogenic genes, such as PAX7 (Darabi et al, 2012; Skoglund et al, 2014) and MYOD1 (Tanaka et al, 2013; Abujarour et al, 2014; Yasuno et al, 2014; Maffioletti et al, 2015). Although transgene-based approaches yield SMPCs with high efficiency, the resulting cells may not fully reflect the natural endogenous processes of SMPC proliferation, differentiation, and maturation, because such overexpression requires genetic modification (reviewed in Jiwlawat et al, 2018).…”

Section: Remaining Challenges To Isolate Human Smpcs From Pluripotentmentioning

confidence: 99%

Coding Cell Identity of Human Skeletal Muscle Progenitor Cells Using Cell Surface Markers: Current Status and Remaining Challenges for Characterization and Isolation

Tey

Robertson

Lynch

et al. 2019

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Skeletal muscle progenitor cells (SMPCs), also called myogenic progenitors, have been studied extensively in recent years because of their promising therapeutic potential to preserve and recover skeletal muscle mass and function in patients with cachexia, sarcopenia, and neuromuscular diseases. SMPCs can be utilized to investigate the mechanisms of natural and pathological myogenesis via in vitro modeling and in vivo experimentation. While various types of SMPCs are currently available from several sources, human pluripotent stem cells (PSCs) offer an efficient and cost-effective method to derive SMPCs. As human PSC-derived cells often display varying heterogeneity in cell types, cell enrichment using cell surface markers remains a critical step in current procedures to establish a pure population of SMPCs. Here we summarize the cell surface markers currently being used to detect human SMPCs, describing their potential application for characterizing, identifying and isolating human PSC-derived SMPCs. To date, several positive and negative markers have been used to enrich human SMPCs from differentiated PSCs by cell sorting. A careful analysis of current findings can broaden our understanding and reveal potential uses for these surface markers with SMPCs.

show abstract

Section: Remaining Challenges To Isolate Human Smpcs From Pluripotentmentioning

confidence: 99%

Coding Cell Identity of Human Skeletal Muscle Progenitor Cells Using Cell Surface Markers: Current Status and Remaining Challenges for Characterization and Isolation

Tey

Robertson

Lynch

et al. 2019

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Activation of MYOD in a variety of differentiated cell lines is sufficient to activate a downstream program for terminal muscle differentiation [200]. Different systems of gene expression, such as lentiviral and piggyBac-based approaches, are used to express PAX7 and MYOD1 in iPSCs [161,201]. MYOD1 overexpression, particularly in undifferentiated cells, drives them along the myogenic lineage with 70-90% efficiency, and myocytes reach maturity within two weeks of differentiation [161].…”

Section: Overexpression Of Muscle-specific Transcription Factorsmentioning

confidence: 99%

“…Different systems of gene expression, such as lentiviral and piggyBac-based approaches, are used to express PAX7 and MYOD1 in iPSCs [161,201]. MYOD1 overexpression, particularly in undifferentiated cells, drives them along the myogenic lineage with 70-90% efficiency, and myocytes reach maturity within two weeks of differentiation [161]. Overexpression of PAX7 in two well-characterized human iPSC lines, generated from normal donor's fibroblasts, converts these cells into myotubes [201].…”

Section: Overexpression Of Muscle-specific Transcription Factorsmentioning

confidence: 99%

Insulin/Glucose-Responsive Cells Derived from Induced Pluripotent Stem Cells: Disease Modeling and Treatment of Diabetes

Gheibi

Singh

Cunha

et al. 2020

Cells

View full text Add to dashboard Cite

Type 2 diabetes, characterized by dysfunction of pancreatic β-cells and insulin resistance in peripheral organs, accounts for more than 90% of all diabetes. Despite current developments of new drugs and strategies to prevent/treat diabetes, there is no ideal therapy targeting all aspects of the disease. Restoration, however, of insulin-producing β-cells, as well as insulin-responsive cells, would be a logical strategy for the treatment of diabetes. In recent years, generation of transplantable cells derived from stem cells in vitro has emerged as an important research area. Pluripotent stem cells, either embryonic or induced, are alternative and feasible sources of insulin-secreting and glucose-responsive cells. This notwithstanding, consistent generation of robust glucose/insulin-responsive cells remains challenging. In this review, we describe basic concepts of the generation of induced pluripotent stem cells and subsequent differentiation of these into pancreatic β-like cells, myotubes, as well as adipocyte- and hepatocyte-like cells. Use of these for modeling of human disease is now feasible, while development of replacement therapies requires continued efforts.

show abstract

“…One major obstacle is the development of a safe and pure myogenic cell population from iPSCs. This traditionally has been done using gene-overexpression or directed differentiation using small molecules or cytokines [30,31,41,55,56,57,58]. Although both methods demonstrated promising advances in the generation of the myogenic cells from iPSCs, there are still a few major concerns.…”

Section: Perspective For Therapeutic Application Of Ipscs In Muscumentioning

confidence: 99%

iPSCs as a Platform for Disease Modeling, Drug Screening, and Personalized Therapy in Muscular Dystrophies

Ortiz-Vitali

Darabi

2019

Cells

View full text Add to dashboard Cite

Induced pluripotent stem cells (iPSCs) are the foundation of modern stem cell-based regenerative medicine, especially in the case of degenerative disorders, such as muscular dystrophies (MDs). Since their introduction in 2006, many studies have used iPSCs for disease modeling and identification of involved mechanisms, drug screening, as well as gene correction studies. In the case of muscular dystrophies, these studies commenced in 2008 and continue to address important issues, such as defining the main pathologic mechanisms in different types of MDs, drug screening to improve skeletal/cardiac muscle cell survival and to slow down disease progression, and evaluation of the efficiency of different gene correction approaches, such as exon skipping, Transcription activator-like effector nucleases (TALENs), Zinc finger nucleases (ZFNs) and RNA-guided endonuclease Cas9 (CRISPR/Cas9). In the current short review, we have summarized chronological progress of these studies and their key findings along with a perspective on the future road to successful iPSC-based cell therapy for MDs and the potential hurdles in this field.

show abstract

Correction: Efficient and Reproducible Myogenic Differentiation from Human iPS Cells: Prospects for Modeling Miyoshi Myopathy In Vitro

Cited by 49 publications

References 0 publications

Coding Cell Identity of Human Skeletal Muscle Progenitor Cells Using Cell Surface Markers: Current Status and Remaining Challenges for Characterization and Isolation

Coding Cell Identity of Human Skeletal Muscle Progenitor Cells Using Cell Surface Markers: Current Status and Remaining Challenges for Characterization and Isolation

Insulin/Glucose-Responsive Cells Derived from Induced Pluripotent Stem Cells: Disease Modeling and Treatment of Diabetes

iPSCs as a Platform for Disease Modeling, Drug Screening, and Personalized Therapy in Muscular Dystrophies

Contact Info

Product

Resources

About